Loading...
ALC logo

Alcon Inc.Informe acción NYSE:ALC

Capitalización bursátil US$34.5b
Precio de las acciones
n/a
1Y-17.0%
7D2.7%
1D1.1%
Valor de la cartera
Ver

Alcon Inc.

Informe acción NYSE:ALC

Capitalización de mercado: US$34.5b

Alcon (ALC) Resumen de Acciones

Alcon Inc. investiga, desarrolla, fabrica, distribuye y vende productos oftalmológicos en todo el mundo. Saber más

Análisis fundamental de ALC
Puntuación del snowflake
Valoración3/6
Crecimiento futuro2/6
Rendimiento pasado2/6
Salud financiera6/6
Dividendos0/6

ALC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW485,942 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
485,942 investors already sharing narratives

Competidores de Alcon Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Alcon
Precios históricos de las acciones
Precio actual de la acciónCHF 70.99
Máximo en las últimas 52 semanasCHF 90.41
Mínimo de 52 semanasCHF 61.84
Beta0.69
Cambio en 1 mes1.91%
Variación en 3 meses8.53%
Cambio de 1 año-17.01%
Variación en 3 años-12.74%
Variación en 5 años-1.00%
Variación desde la OPV22.31%

Noticias y actualizaciones recientes

Seeking Alpha May 31

Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)

Summary Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks. Key risks include payer restrictions, patient tolerability, competition, and potential growth deceleration post-2026. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha May 31

Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)

Summary Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks. Key risks include payer restrictions, patient tolerability, competition, and potential growth deceleration post-2026. Read the full article on Seeking Alpha
Seeking Alpha Feb 04

Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation

Summary Alcon is downgraded to a hold from my buy rating in fall 2023, after it has gone up +18% since then and now appears overvalued with a 48x earnings multiple. The firm has a strong profit margin vs its sector, low debt/equity vs a key peer Bausch & Lomb, and investment-grade credit ratings. Its positive cashflow growth should help sustain its dividend. Some risks in this sector are product recalls and supply-chain disruptions, as past events have shown us. Read the full article on Seeking Alpha
Seeking Alpha Sep 04

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Summary I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set for U.S. commercialization in 2025, enhancing their competitive edge in cataract and vitreoretinal surgery markets. Alcon's partnership with Ocumension in China will leverage local distribution and manufacturing to expand their dry eye treatment business, including Systane Ultra and AR-15512. Despite some U.S. market challenges, I project Alcon to achieve 7% organic revenue growth, supported by product innovation and strategic acquisitions. Read the full article on Seeking Alpha
Seeking Alpha Aug 01

Alcon: Trading At An Undeserved Premium Valuation

Summary Global eye care giant Alcon, Inc. has seen its stock rise some 30% since its late October lows. The company is delivering solid, but hardly spectacular revenue growth, and is seeing much better free cash flow. The stock now trades at a significant valuation premium to the overall market. Is that premium valuation deserved? An analysis of Alcon follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha May 14

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Summary Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product launches, such as TOTAL30 and DAILIES TOTAL1, which have helped Alcon gain market share. Alcon's FY24 forecast shows potential for increased free cash flow, strong revenue growth in vision care, and growth opportunities in the surgical business. Read the full article on Seeking Alpha
Seeking Alpha Oct 10

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Summary Alcon gets a Buy Rating today, in line with Wall Street consensus. Strengths include earnings growth, share price crossover below 200-day average, outperformance vs. the S&P500 index, and the company's strong cash position. Offsetting factors include a high valuation and poor dividend yield. The downside risk of debt levels was also addressed. Read the full article on Seeking Alpha
Seeking Alpha Jul 26

Alcon: Lackluster Growth Given Its Valuation

Summary Alcon stock is currently trading at over 30x earnings, which is considered high for a company not expected to deliver EPS above 20 - 25% in the next few years. Despite the high trading multiple, Alcon has a strong business model and is a leader in the eye care industry, with recent positive developments in its product line and services. Alcon's share price is currently inflated due to hopes of significant free cash flow being diverted to shareholders, but I suggest this optimism may be misplaced and recommend a hold rating for the company. Read the full article on Seeking Alpha
Seeking Alpha Jun 27

Alcon: The Steady Force Of 'Boring'

Summary Alcon is expected to outpace market growth and gain market share in the surgical and vision care sectors, with growth driven by factors such as the increasing global aging population and rise in myopia. Along with Costco, Aon, and Marsh & McLennan, Alcon is another "boring" investment in my portfolio. Alcon's focus on R&D, product innovation, and accelerated free cash flow generation contribute to a positive outlook, earning a "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha Feb 13

Alcon reached $199M settlement with J&J Surgical Vision

Eye care company Alcon (NYSE:ALC) has reached a settlement with J&J Surgical Vision on its pending legal proceedings related to femtosecond laser assisted cataract surgery devices. The parties have exchanged cross-licenses of certain intellectual property and other mutually agreed covenants and releases, as part of the settlement. In addition, Alcon (ALC) has agreed to make a one-time payment of $199M to J&J Surgical Vision for those rights and to resolve various worldwide IP disputes relating to this matter.

Rentabilidad de los accionistas

ALCUS Medical EquipmentMercado US
7D2.7%2.3%2.4%
1Y-17.0%-12.8%19.6%

Rentabilidad vs. Industria: Los resultados de ALC fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -12.8% el año pasado.

Rentabilidad vs. Mercado: ALC obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.6% el año pasado.

Volatilidad de los precios

Is ALC's price volatile compared to industry and market?
ALC volatility
ALC Average Weekly Movement5.2%
Medical Equipment Industry Average Movement8.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: ALC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ALC (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
194525,000David Endicottwww.alcon.com

Alcon Inc. investiga, desarrolla, fabrica, distribuye y vende productos oftalmológicos en todo el mundo. La empresa opera a través de dos segmentos, Surgical y Vision Care. Ofrece equipos, instrumentación y diagnósticos, lentes intraoculares (LIO) y otros implantables; y consumibles, incluidos viscoelásticos, soluciones quirúrgicas, instrumentos de incisión, paquetes quirúrgicos personalizados y otros productos para procedimientos quirúrgicos.

Resumen de fundamentos de Alcon Inc.

¿Cómo se comparan los beneficios e ingresos de Alcon con su capitalización de mercado?
Estadísticas fundamentales de ALC
Capitalización bursátilUS$34.48b
Beneficios(TTM)US$819.00m
Ingresos (TTM)US$10.63b
42.1x
Ratio precio-beneficio (PE)
3.2x
Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ALC
IngresosUS$10.63b
Coste de los ingresosUS$4.66b
Beneficio brutoUS$5.97b
Otros gastosUS$5.15b
BeneficiosUS$819.00m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

Aug 11, 2026

Beneficios por acción (BPA)1.68
Margen bruto56.14%
Margen de beneficio neto7.70%
Ratio deuda/patrimonio21.4%

¿Cómo se ha desempeñado ALC a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

0.5%
Rentabilidad actual por dividendo
21%
Ratio de pagos

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/08/04 01:35
Precio de las acciones al final del día2026/08/04 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Alcon Inc. está cubierta por 58 analistas. 23 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
null nullArgus Research Company
null nullBaird
Jeffrey JohnsonBaird